Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas

[1] Ferlay J(2019)Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 1941-1953

[2] Colombet M(2016)Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Lancet Oncol 17 717-726

[3] Soerjomataram I(2018)Implications of the tumor immune microenvironment for staging and therapeutics Mod Pathol 31 214-234

[4] Muro K(2015)PD-1/PD-L1 inhibitors Curr Opin Pharmacol 23 32-38

[5] Chung HC(2014)Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation Cancer J 20 256261-281

[6] Shankaran V(2018)PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers Oncoimmunology. 7 e1433520-499

[7] Taube JM(2012)Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 12 269-3029

[8] Galon J(2011)T cell exhaustion Nat Immunol 12 492-571

[9] Sholl LM(2009)PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J Exp Med 206 3015-11091

[10] Sunshine J(2014)PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature. 515 568-80434

[1] Ferlay J(2019)Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 144 1941-1953

[2] Colombet M(2016)Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Lancet Oncol 17 717-726

[3] Soerjomataram I(2018)Implications of the tumor immune microenvironment for staging and therapeutics Mod Pathol 31 214-234

[4] Muro K(2015)PD-1/PD-L1 inhibitors Curr Opin Pharmacol 23 32-38

[5] Chung HC(2014)Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation Cancer J 20 256261-281

[6] Shankaran V(2018)PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers Oncoimmunology. 7 e1433520-499

[7] Taube JM(2012)Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 12 269-3029

[8] Galon J(2011)T cell exhaustion Nat Immunol 12 492-571

[9] Sholl LM(2009)PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J Exp Med 206 3015-11091

[10] Sunshine J(2014)PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature. 515 568-80434